Mylan N.V. (NASDAQ:MYL) & NephroGenex (NRX) Head-To-Head Comparison

Mylan N.V. (NASDAQ: MYL) and NephroGenex (NASDAQ:NRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitabiliy, earnings and dividends.

Institutional & Insider Ownership

70.2% of Mylan N.V. shares are owned by institutional investors. 0.7% of Mylan N.V. shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Mylan N.V. and NephroGenex, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mylan N.V.	0	8	11	2	2.71
NephroGenex	0	0	1	0	3.00

Mylan N.V. currently has a consensus target price of $50.05, indicating a potential upside of 57.45%. NephroGenex has a consensus target price of $17.50, indicating a potential upside of 12,391.08%. Given NephroGenex’s stronger consensus rating and higher probable upside, analysts plainly believe NephroGenex is more favorable than Mylan N.V..

Valuation and Earnings

This table compares Mylan N.V. and NephroGenex’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
Mylan N.V.	$11.61 billion	1.47	$3.80 billion	$1.00	31.79
NephroGenex	N/A	N/A	N/A	N/A	N/A

Mylan N.V. has higher revenue and earnings than NephroGenex.

Profitability

This table compares Mylan N.V. and NephroGenex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mylan N.V.	4.59%	23.69%	7.92%
NephroGenex	N/A	-211.97%	-105.90%

Summary

Mylan N.V. beats NephroGenex on 8 of the 10 factors compared between the two stocks.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

NephroGenex Company Profile

NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.